- HEPATIC METABOLITE PRODUCTION-

NO innovation for life

INTRODUCTION

- Drug metabolites are needed during various phases of drug development of small molecules.
- Current production platforms produce low amounts of metabolites (in vitro/chemical), are difficult to scale, and often require long timelines (weeks to months).



SOLUTION

Normothermic perfusion of slaughterhouse porcine livers to produce (human-like) hepatic kinetic & metabolite profile and production of (multiple) metabolites.



REFERENCES

¹Stevens et al., Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins; Drug Metab Dispos 49:780–789, 2021

Figure 1. Graphical representation of ex vivo liver perfusion with the option to connect a kidney as well, thereby generating perfusate, bile and urine fractions.

PROCEDURE

- 1. Shipment of compound
- 2. Feasibility of hepatic metabolite production in human and porcine liver microsomes
- 3. Upon go: perform normothermic liver perfusion experiment with continuous (increasing) dose of test compound
- 4. Optional: combined liver-kidney perfusion
- 5. Collection of perfusate (plasma), bile (and urine) samples over period of approximately 6h
- 6. Shipment of perfusate, bile (and urine)
- 7. Optional next step: isolation and purification of metabolites

EXAMPLE



Figure 2. Metabolism of midazolam in the liver by CYP3A4/5 and UGTsv

In a single normothermic liver perfusion experiment ~3,5 mg of Midazolam 1'-O-glucuronide was produced

YOUR BENEFITS

- Fast production of hepatic metabolites in mg range
- All hepatic metabolites formed in 1 run
- Fast production & short run time (within 1-2 weeks)
- Option to combine with kidney perfusion in order to produce/isolate renal metabolites

TNO HEALTHY LIVING

TNO initiates technological and societal innovation for healthy living and a dynamic society.

TNO Utrechtseweg 48 3704 HE Zeist, The Netherlands

Steven Erpelinck P +31 88 866 16 49 E steven.erpelinck@tno.nl